WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up ...

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac, a deal that was announced in June.

Researchers at UF Health and the University of Texas MD Anderson have found that cancer patients may live longer if they ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to ...

RNA vaccines seem to boost the effectiveness of an immune therapy for skin and lung cancer ― in an unexpected way.

Cancer patients who received the mRNA-based jab after starting immunotherapy lived significantly longer than those who did ...

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...

Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology. He's seen here at a Sept. 4, 2025, hearing before the Senate Finance ...

Many scientists have celebrated the use of mRNA to fight COVID-19, with the two researchers behind this advance winning a Nobel Prize in 2023. Most experts agree that mRNA vaccines saved millions of ...

Immunotherapies have made significant strides in treating advanced cancers, a feat that was once considered impossible. These treatments, with their potential for long-lasting responses, have ...

This month, the Department of Health and Human Services terminated almost $500 million in mRNA vaccine development grants and contracts. While HHS has said that these cuts won’t affect mRNA cancer ...

"From the instant the coronavirus invaded our shores, we raced into action to develop a safe and effective vaccine at breakneck speed… We harnessed the full power of government, the genius of American ...